Treatment outcome measures for randomized controlled trials of antibiotic treatment for acute bacterial skin and skin structure infections in the emergency department setting

Table 1 Summary of relevant nomenclature issued by the US FDA and the Infectious Diseases Society of America (IDSA)

Source	Descriptor	Clinical conditions included
FDA 1998 [22]	Uncomplicated skin and skin structure infection	Abscess, cellulitis, impetigo, furuncle
	Complicated skin and skin structure and soft tissue infection	Infections of deeper soft tissue or requiring significant surgical intervention (infected ulcers, burns, major abscess), or a significant underlying disease state that complicates response to treatment
FDA 2010 [23] and 2013 [1]	Acute bacterial skin and skin structure infections (ABSSSIs)	Bacterial infection of the skin with a minimum size of >75 cm². Includes:
FDA 2010 [23] and 2013 [1]		•Cellulitis/erysipelas
		•Wound infection
		•Major cutaneous abscess
IDSA 2011 [24]	Purulent cellulitis	Cellulitis associated with purulent drainage or exudate in the absence of a drainable abscess
IDSA 2011 [24]	Non-purulent cellulitis	Cellulitis with no purulent drainage or exudate and no associated abscess
IDSA 2014 [25]	Purulent skin and soft tissue infection (SSTI)	Abscess, furuncle, carbuncle, inflamed epidermoid cyst
	Non-purulent SSTI	Cellulitis, erysipelas, necrotizing fasciitis

ISSN: 1865-1380